These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 36154607)

  • 1. Advances on Epigenetic Drugs for Pediatric Brain Tumors.
    Skouras P; Markouli M; Strepkos D; Piperi C
    Curr Neuropharmacol; 2023; 21(7):1519-1535. PubMed ID: 36154607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pediatric brain tumors: the era of molecular diagnostics, targeted and immune-based therapeutics, and a focus on long term neurologic sequelae.
    Plant-Fox AS; O'Halloran K; Goldman S
    Curr Probl Cancer; 2021 Aug; 45(4):100777. PubMed ID: 34303558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pediatric high-grade glioma: aberrant epigenetics and kinase signaling define emerging therapeutic opportunities.
    Sun Y; Bailey CP; Sadighi Z; Zaky W; Chandra J
    J Neurooncol; 2020 Oct; 150(1):17-26. PubMed ID: 32504402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in the molecular classification of pediatric brain tumors: a guide to the galaxy.
    Cacciotti C; Fleming A; Ramaswamy V
    J Pathol; 2020 Jul; 251(3):249-261. PubMed ID: 32391583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanisms and therapeutic targets in pediatric brain tumors.
    Liu KW; Pajtler KW; Worst BC; Pfister SM; Wechsler-Reya RJ
    Sci Signal; 2017 Mar; 10(470):. PubMed ID: 28292958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Developmental origins and oncogenic pathways in malignant brain tumors.
    Lu QR; Qian L; Zhou X
    Wiley Interdiscip Rev Dev Biol; 2019 Jul; 8(4):e342. PubMed ID: 30945456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging Epigenetic Therapies for Brain Tumors.
    Kukreja L; Li CJ; Ezhilan S; Iyer VR; Kuo JS
    Neuromolecular Med; 2022 Mar; 24(1):41-49. PubMed ID: 34677796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic-Based Therapy-A Prospective Chance for Medulloblastoma Patients' Recovery.
    Strejczek A; Woszczyk D; Urbaniak H; Różańska M; Robak M; Matuszewska Z; Barciszewska AM
    Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34066495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuro-oncology: Genetic variation in pediatric and adult brain tumors.
    Brandes AA; Franceschi E
    Nat Rev Neurol; 2010 Dec; 6(12):653-4. PubMed ID: 21131914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of the genomic landscape of common pediatric CNS tumors and how data sharing will continue to shape this landscape in the future.
    Kaneva K; Goldman S
    Mol Biol Rep; 2021 Nov; 48(11):7537-7544. PubMed ID: 34643931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic regulation in medulloblastoma.
    Yi J; Wu J
    Mol Cell Neurosci; 2018 Mar; 87():65-76. PubMed ID: 29269116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multidisciplinary management of childhood brain tumors: a review of outcomes, recent advances, and challenges.
    Pollack IF
    J Neurosurg Pediatr; 2011 Aug; 8(2):135-48. PubMed ID: 21806354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological background of pediatric medulloblastoma and ependymoma: a review from a translational research perspective.
    de Bont JM; Packer RJ; Michiels EM; den Boer ML; Pieters R
    Neuro Oncol; 2008 Dec; 10(6):1040-60. PubMed ID: 18676356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medulloblastoma and ependymoma cells display increased levels of 5-carboxylcytosine and elevated
    Ramsawhook A; Lewis L; Coyle B; Ruzov A
    Clin Epigenetics; 2017; 9():18. PubMed ID: 28228863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic events in medulloblastoma development.
    Lindsey JC; Anderton JA; Lusher ME; Clifford SC
    Neurosurg Focus; 2005 Nov; 19(5):E10. PubMed ID: 16398460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetics and survivorship in pediatric brain tumor patients.
    Bhattacharya D; Pomeroy SL; Pomeranz Krummel DA; Sengupta S
    J Neurooncol; 2020 Oct; 150(1):77-83. PubMed ID: 32451770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transitioning from genotypes to epigenotypes: why the time has come for medulloblastoma epigenomics.
    Batora NV; Sturm D; Jones DT; Kool M; Pfister SM; Northcott PA
    Neuroscience; 2014 Apr; 264():171-85. PubMed ID: 23876321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.
    Henssen A; Thor T; Odersky A; Heukamp L; El-Hindy N; Beckers A; Speleman F; Althoff K; Schäfers S; Schramm A; Sure U; Fleischhack G; Eggert A; Schulte JH
    Oncotarget; 2013 Nov; 4(11):2080-95. PubMed ID: 24231268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential Signaling Pathways in Medulloblastoma: Nano-biomedicine Targeting Non-coding Epigenetics to Improve Current and Future Therapeutics.
    Sokolov D; Sharda N; Banerjee A; Denisenko K; Basalious EB; Shukla H; Waddell J; Hamdy NM; Banerjee A
    Curr Pharm Des; 2024; 30(1):31-47. PubMed ID: 38151840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma.
    Kling MJ; Kesherwani V; Mishra NK; Alexander G; McIntyre EM; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
    J Exp Clin Cancer Res; 2022 Nov; 41(1):321. PubMed ID: 36357906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.